having significantly higher serum insulin and a significantly lower serum glucose concentration.
Horses diagnosed with hyperinsulinemia at any time during hospitalization were 4 times more likely to survive whereas horses that were hyperglycemic at any time during hospitalization were 5 times less likely to survive. Serum glucose concentration and presence of hyperglycemia both were associated with severity of disease. Insulin/glucose ratio, reflecting insulin secretion, was significantly higher in survivors whereas glucose/insulin ratio, reflecting peripheral tissue insulin resistance, was significantly lower in nonsurvivors. Only in survivors was there a significant correlation between serum insulin and glucose concentrations.
Conclusions and Clinical Importance: Hyperinsulinemia and hyperglycemia are common features of SIRS in horses, but those presenting with relative hypoinsulinemia and corresponding hyperglycemia suggestive of endocrine pancreatic dysfunction have a worse prognosis.
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| IN TR ODUC TION
Systemic inflammation is associated with peripheral tissue insulin resistance and hyperglycemia in many species. [1] [2] [3] [4] Insulin regulates lipid and carbohydrate metabolism by increasing glucose uptake from the blood to insulin-sensitive tissues such as skeletal muscle, adipose tissue and liver. 5 High concentrations of circulating insulin promote the transformation of glucose into glycogen by glycogenesis (skeletal muscles and liver) or into triglycerides by lipogenesis (adipose tissue and liver)
whereas low concentrations of circulating insulin increase hepatic glucose secretion by promoting gluconeogenesis and glycogenolysis. 5, 6 Abbreviations: EMS, equine metabolic syndrome; OR, odds ratio; LPS, lipopolysaccharide; PPID, pituitary pars intermedia dysfunction; ROC, receiver operating characteristic; SIRS, systemic inflammatory response syndrome.
Insulin resistance is the failure of such tissues to respond to endogenous or exogenous insulin, resulting in uncontrolled hyperglycemia. 7, 8 At a cellular level, insulin resistance is thought to develop by several mechanisms: decreased availability of the insulin receptor as a result of cellular hypoxia and oxidative stress causing activation of inflammatory pathways and inhibition of post-receptor insulin signaling pathways. 9 In people, peripheral tissue insulin resistance and hyperglycemia are described commonly with sepsis or severe trauma and high blood glucose concentration has been associated with increased risk of death and poor outcome. 7, 8, [10] [11] [12] In critically ill patients, tight regulation of blood glucose concentration between 80 and 110 mg/dL by intensive insulin treatment has been associated with improved survival. 8 However, other studies have shown that intensive insulin treatment significantly increases the risk of hypoglycemia, also associated with poor survival, conferring no overall mortality benefit among critically ill patients. [13] [14] [15] Finally, other studies found that less stringent regulation of blood glucose concentration (between 140 and 180 mg/dL) by insulin treatment resulted in a decreased incidence of hypoglycemia without increased mortality rate, suggesting that cautious insulin treatment may be warranted in critically ill patients. [16] [17] [18] In equids, systemic inflammation also has been associated with insulin dysregulation: lipopolysaccharide (LPS) infusion has been shown to result in peripheral tissue insulin resistance, and acute gastrointestinal disease results in hyperglycemia, also suggesting peripheral tissue insulin resistance. 3, 19, 20 Similar to what has been described in people, in both foals and adult horses suffering from systemic diseases, hyperglycemia and peripheral tissue insulin resistance have been associated with increased mortality. 21, 22 Nevertheless, several studies in horses also have reported low serum insulin concentration and improved insulin sensitivity in the early stages of systemic inflammation. 20, 23, 24 For example, in sick foals, relative hypoinsulinemia with appropriate blood glucose concentration response has been described. 25 In addition, septic foals have been reported to have increased insulin sensitivity in the early stages of sepsis. 23 Similar observations have been made in adult horses in which transiently improved insulin sensitivity was documented after LPS infusion. 20 In that study, acute pancreatic inhibition of insulin production in response to LPS was observed, suggesting that LPS-associated hyperglycemia could result from pancreatic dysfunction in addition to peripheral insulin resistance. 20 Data collected included signalment, physical examination findings at presentation, routine blood test results at presentation (hematologic and biochemical data), diagnosis, in-hospital treatments (including surgery), duration of hospitalization, outcome, and type of intestinal lesion (ischemic lesion or not) for horses that underwent surgery or necropsy. Serum insulin and glucose concentrations were measured from samples collected at admission (after an estimated fasting time of at least 3 hours) and on days 2, 4, and 6 in the morning before feeding.
In the first days of hospitalization, many horses were either anorexic, or having feed withheld or receiving minimal feed, limiting possible diet-induced changes in insulin and glucose dynamics. Blood was collected by either venipuncture or through an aseptically placed IV catheter and placed in a plain glass tube. Blood was allowed to clot for 45 minutes at room temperature and centrifuged. Serum then was isolated and frozen at 2808C until assayed. Equine serum insulin was measured using a radioimmunoassay previously validated in horses (intra-and inter-assay variation: 5.2% and 6.4%, respectively) and blood glucose concentration was measured using a glucohexokinase colorimetric assay as previously described. 32, 33 A diagnosis of hyperinsulinemia was made if serum insulin concentration was >20 mIU/mL and a diagnosis of severe hyperinsulinemia was made if serum insulin concentration was >50 mIU/mL. 
| Data analysis
Horses were categorized based on survival, hyperinsulinemia, hyperglycemia, and number of SIRS criteria and compared with P < .05 considered statistically significant. Normality was assessed by a Shapiro-Wilk normality test. Data following a normal distribution were reported as mean 6 SD and compared using an unpaired t-test, whereas data not following a normal distribution were reported as median (range) and compared using a 
| R E SULTS

| Animal population
Fifty-eight horses met the inclusion criteria. Horses ranged from 5 to 32 years of age with a median age of 11 years. Twenty-two horses (38%) were female and 36 (62%) were male, including 34 geldings (94% of males) and 2 stallions (6% of males). Breeds included Quarter Horse and associated breeds (25 horses, 43%), Thoroughbred (7 horses, 12%), Warmblood (5 horses, 9%), Arab (5 horses, 9%), Pony (3 horses, 5%), draft (3 horses, 5%), and mixed and other breeds (10 horses, 17%)
reflecting the hospital population.
| Clinical data
The most common clinical signs reported were tachycardia (53 horses, 91%), tachypnea (51 horses, 88%), prolonged capillary refill time (17 horses, 29%), and pyrexia (7 horses, 13% Figure 1 ). Presence of hyperinsulinemia at any time during hospitalization (Day 0, 2, 4, or 6) was associated with survival (P 5 .02, Table 1 ) with hyperinsulinemic horses 4 times more likely to survive. Severe hyperinsulinemia (insulin > 50 mIU/mL) was diagnosed in 6 horses but was not associated with survival (P 5 .39). Serum insulin and hyperinsulinemia at any time during hospitalization were not associated with SIRS group (P 5 .90 and P 5 .56, respectively).
The ROC curve showed that a serum insulin concentration >8.82 mIU/mL (the algorithm's suggested optimal cutoff) was a poor FIGURE 1 Serum insulin concentration (mIU/mL) at admission in nonsurvivors and survivors (*P < .05) 
| Glucose
Hyperglycemia (>124 mg/dL) was diagnosed, at admission, in 44 horses (88%) and was associated with nonsurvival (P 5 .03, Figure 2 ). Serum glucose concentration and presence of hyperglycemia both were associated with SIRS group (P < .001, Figure 3 , and P < .01, respectively).
Using an optimal cutoff value of 150 mg/dL, the ROC curve showed that serum glucose concentration was a poor diagnostic test to predict survival with an area under the ROC curve of 0.66, yielding a sensitivity of 71.4% (47.8%-88.7%) and a specificity of 63.9% (46.2%-79.2%).
| Ratios and correlations
Insulin/glucose ratio, reflecting insulin secretion, was significantly P < .01, Figure 5 ). A glucose/insulin ratio < 10, indicative of peripheral tissue insulin resistance, was found in 22 horses (38%) but was not associated with a final outcome of survival (P 5 .06). 36 A glucose/ insulin ratio < 4.5, indicative of severe peripheral tissue insulin resistance, was found in 8 horses (14%) but was not associated with survival (P 5 .11). 36 Using an optimal cutoff value of 12.5, the ROC curve showed that the glucose/insulin ratio was a fair diagnostic test to predict survival with an area under the ROC curve of 0.73, yielding a sensitivity of 71.4% (47.8%-88.7%) and specificity of 68.6% (50.7%-83.2%).
Overall, no correlation was found between serum insulin concentration and glucose concentration at admission (P 5 .13) but in survivors, a significant correlation was found between serum insulin and glucose concentrations (P 5 .002, R 2 5 .25 Figure 6 ).
| D ISC USSION
Our main finding was the association between hyperinsulinemia and favorable outcome and the association between hyperglycemia and poor outcome, suggesting that an appropriate pancreatic response to SIRS-associated hyperglycemia is associated with survival. FIGURE 4 Insulin/glucose ratio, reflecting insulin secretion, in nonsurvivors, and survivors (*P < .05) FIGURE 5 Glucose/insulin ratio, reflecting insulin sensitivity, in nonsurvivors, and survivors (*P < .05) between chronic or intermittent hyperinsulinemia and obesity is a wellrecognized phenomenon in equine endocrinology but limited data are available regarding the association between acute SIRS-induced hyperinsulinemia and survival. 38 Experimental infusion of LPS resulted in increases in serum insulin concentration, suggesting that hyperinsulinemia would develop in acutely sick horses. 3, 20, 39 However, in 1 of these studies, insulin secretion was biphasic after LPS infusion. 20 Although few horses were included in that study, LPS initially induced a mild decrease in serum insulin concentration before causing a more pronounced increase. This finding suggests inhibition of pancreatic b cell function in the early phases of endotoxemia. In foals, as well as in other species suffering from severe systemic inflammation, a state of relative hypoinsulinemia has been described. 23, 40, 41 In those cases, relative hypoinsulinemia was defined as a failure of insulin secretion in the face of SIRS-induced hyperglycemia, suggesting a transient diabetes mellitus, which is rarely reported in horses. Type-1 diabetes mellitus, more commonly diagnosed in humans or in dogs, is observed as a consequence of immune-mediated damage to the endocrine pancreas whereas type-2 diabetes mellitus develops after decreased pancreatic b cell function after sustained hyperinsulinemia. 42, 43 In 1 foal with severe SIRS, a transient type-1 diabetes mellitus has been described suggesting that severe SIRS could lead to pancreatic dysfunction. 44 In agreement with those reports, our data indicate that severe hyperglycemia, in the face of an inadequate insulin response, is associated with non-survival and reflects a possible state of relative hypoinsulinemia or inappropriate lack of insulin secretion. In addition, although serum insulin concentration was significantly higher in survivors, it was rarely above reference range (20 mIU/mL) suggesting that, rather than excessive insulin secretion in survivors, decreased insulin secretion was observed in nonsurvivors. Taken together, these data suggest that, in horses, SIRS-associated hyperglycemia is caused by peripheral tissue insulin resistance and by pancreatic dysfunction resulting in decreased insulin secretion.
In our study, hyperglycemia was associated with nonsurvival.
Hyperglycemia previously has been associated with poor outcome in horses suffering from gastrointestinal diseases. 21 In human medicine, large-scale studies indicated that, in acutely ill patients in critical care units, prolonged hyperglycemia was associated with cardiovascular dysfunction, respiratory failure, increased odds of infection and worse neurological status. 12, [45] [46] [47] In those studies, the explanations for hyperglycemia in critically ill patients included stress-associated cortisol secretion, peripheral insulin resistance, hyperinsulinemia, and increased gluconeogenesis. 14, 21 In our study, several variables such as serum insulin concentration and glucose/insulin ratio suggest that horses with SIRS also suffered from insulin dysregulation, at least partly caused by peripheral tissue insulin resistance. In our study, the larger the number of SIRS criteria, and presumably the sicker the animal, the higher the serum glucose concentration, suggesting that hyperglycemia could be used to estimate severity of SIRS in equine patients. However, given our small sample size, no actual validation of the grouping system could be performed and cautious interpretation is warranted. Nevertheless, in our sample, nonsurvivors had a significantly larger number of SIRS criteria than did survivors (P < .05). In critically ill people, serum glucose concentration is used as a prognostic indicator, and associations between specific outcomes and blood glucose concentration thresholds have been made. 14 However, if serum glucose concentration is used to estimate the severity of disease, it should not be used to predict survival in horses with SIRS based on its mediocre sensitivity and specificity in our study.
In our study, the insulin/glucose ratio was lower in nonsurvivors.
This ratio is used to estimate pancreatic insulin secretion in response to a glycemic challenge. 34 Although the use of proxies, such as this ratio,
has not been fully validated in horses, this difference between survivors and nonsurvivors confirms that the degree of pancreatic dysfunction in nonsurvivors was worse than in survivors. In our study, no dynamic testing was performed to assess pancreatic function, but our data indicate that horses with SIRS may experience a transient dysfunction of the endocrine pancreas. In horses, the main driver for insulin secretion is blood glucose concentration suggesting that in non-survivors decreased insulin responsiveness and decreased insulin sensitivity could be responsible for the observed hyperglycemia. In our study, none of the horses developed laminitis and no conclusion could be drawn on the association between hyperinsulinemia and laminitis in the presence of SIRS. Both hyperglycemia and sepsis Our study is, to our knowledge, the first to provide evidence that horses with naturally occurring SIRS undergo transient pancreatic dysfunction and that persistence of that state, reflected by hyperglycemia and relative hypoinsulinemia, is associated with poor survival. Our study also showed that clinicopathologic evidence of insulin dysregulation, reflected by hyperinsulinemia and peripheral tissue insulin resistance, may not be associated with poor prognosis in the context of SIRS. In such cases, hyperinsulinemia might indicate a better prognosis, because it implies an intact endocrine pancreas capable of responding to SIRS-associated hyperglycemia. Transient mild insulin dysregulation might therefore be an adaptive physiological state that promotes survival, whereas severe insulin dysregulation in the form of inappropriately low insulin concentrations in the face of hyperglycemia appears to be associated with a poor prognosis. As recommended in human medicine, cautious insulin treatment might be beneficial for horses with SIRS presenting with severe unregulated hyperglycemia. 
CONFLICT OF INTEREST DECLARATION
Authors declare no conflict of interest.
OFF-LABEL ANTIMICROBIAL DECLARATION
Authors declare no off-label use of antimicrobials.
INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE (IACUC) OR OTHER APPROVAL DECLARATION
All aspects of the study were approved by the Auburn University 
